BR112013026896A8 - métodos e composições adequadas para prevenir e tratar hiperleptinemia - Google Patents

métodos e composições adequadas para prevenir e tratar hiperleptinemia

Info

Publication number
BR112013026896A8
BR112013026896A8 BR112013026896A BR112013026896A BR112013026896A8 BR 112013026896 A8 BR112013026896 A8 BR 112013026896A8 BR 112013026896 A BR112013026896 A BR 112013026896A BR 112013026896 A BR112013026896 A BR 112013026896A BR 112013026896 A8 BR112013026896 A8 BR 112013026896A8
Authority
BR
Brazil
Prior art keywords
prevention
treatment
compositions
preventing
suitable methods
Prior art date
Application number
BR112013026896A
Other languages
English (en)
Other versions
BR112013026896A2 (pt
Inventor
Paul Middleton Rondo
Pan Yuanlong
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of BR112013026896A2 publication Critical patent/BR112013026896A2/pt
Publication of BR112013026896A8 publication Critical patent/BR112013026896A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Animal Husbandry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fodder In General (AREA)

Abstract

resumo patente de invenção: "métodos e composições adequadas para prevenir e tratar hiperleptinemia". a invenção refere-se a métodos e composições adequados para a prevenção e tratamento de hiperleptinemia, prevenção e tratamento de resistência à insulina, prevenção e tratamento de doenças cardiovasculares, prevenção e tratamento de obesidade, prevenção e tratamento de hiperlipidemia e prevenção e tratamento de hipertensão em um animal. os métodos compreendem a administração de uma ou mais isoflavonas ao animal, de preferência em quantidades de cerca de 0,001 a cerca de 10 g/kg/dia.
BR112013026896A 2011-04-20 2012-04-17 métodos e composições adequadas para prevenir e tratar hiperleptinemia BR112013026896A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161517464P 2011-04-20 2011-04-20
PCT/US2012/033873 WO2012145281A2 (en) 2011-04-20 2012-04-17 Methods and compositions suitable for preventing and treating hyperleptinemia

Publications (2)

Publication Number Publication Date
BR112013026896A2 BR112013026896A2 (pt) 2016-10-18
BR112013026896A8 true BR112013026896A8 (pt) 2018-01-16

Family

ID=47042122

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013026896A BR112013026896A8 (pt) 2011-04-20 2012-04-17 métodos e composições adequadas para prevenir e tratar hiperleptinemia

Country Status (11)

Country Link
US (1) US20140037583A1 (pt)
EP (1) EP2699095A4 (pt)
JP (1) JP2014515756A (pt)
CN (1) CN103608011A (pt)
AU (2) AU2012245639B2 (pt)
BR (1) BR112013026896A8 (pt)
CA (1) CA2833547A1 (pt)
MX (1) MX348902B (pt)
RU (1) RU2607109C2 (pt)
WO (1) WO2012145281A2 (pt)
ZA (1) ZA201308683B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2978454A1 (en) * 2013-03-27 2016-02-03 Ge Healthcare As Method and reagent for preparing a diagnostic composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1171119A1 (en) * 1999-04-20 2002-01-16 The Board Of Trustees Of Southern Illinois University Methods of treating clinical diseases with isoflavones
JP4889944B2 (ja) * 2002-10-29 2012-03-07 コロラド ステート ユニバーシティー リサーチ ファウンデーション アンドロゲンによって仲介される疾患を治療するためのエクオールの使用
ES2559777T3 (es) * 2004-03-17 2016-02-15 Nestec S.A. Composiciones y métodos para reducir o prevenir la obesidad
US20070036873A1 (en) 2005-07-27 2007-02-15 Shibnath Ghosal Method of treatment or management of stress
CA2627915C (en) * 2005-11-02 2015-02-03 Nestec S.A. Isoflavone compositions for reducing accumulation of body fat in male mammals, and methods for their use
EP2063898A4 (en) * 2006-08-18 2012-02-15 Univ Brigham Young USE OF EQUOL TO IMPROVE OR PREVENT NEUROPSYCHIATRIC AND NEURODEGENERATIVE DISEASES OR DISORDERS
AR060847A1 (es) 2007-05-03 2008-07-16 Spannagel Lucia Antonia Formulacion a base de calendula, aloe y centella.
US20090223990A1 (en) * 2008-02-04 2009-09-10 Bailey Kenneth S System for authenticating prescriptive drugs at the time of dispensing
AU2009282482B2 (en) * 2008-08-15 2015-11-26 Société des Produits Nestlé S.A. Methods for enhancing energy metabolism

Also Published As

Publication number Publication date
CN103608011A (zh) 2014-02-26
WO2012145281A3 (en) 2012-12-27
US20140037583A1 (en) 2014-02-06
JP2014515756A (ja) 2014-07-03
MX348902B (es) 2017-07-03
AU2016203821A1 (en) 2016-06-30
AU2012245639A1 (en) 2013-10-31
EP2699095A2 (en) 2014-02-26
BR112013026896A2 (pt) 2016-10-18
MX2013012135A (es) 2013-12-06
RU2607109C2 (ru) 2017-01-10
AU2012245639B2 (en) 2016-06-30
WO2012145281A2 (en) 2012-10-26
ZA201308683B (en) 2015-05-27
EP2699095A4 (en) 2015-04-15
CA2833547A1 (en) 2012-10-26
RU2013151423A (ru) 2015-05-27

Similar Documents

Publication Publication Date Title
CY1123901T1 (el) Φαρμακευτικη συνθεση και χορηγησεις αυτης
BR112014016810A2 (pt) composições e métodos para tratamento de distúrbios metabólicos
BR112018007857A2 (pt) combinações de gemcabene para o tratamento de doença cardiovascular
BR112016029713A2 (pt) métodos para o tratamento de sobrepeso ou obesidade
EP2560660A4 (en) THERAPIES BASED ON CHEMOSOUS RECEPTOR LIGANDS
TN2015000283A1 (fr) Functionalized exendin-4 derivatives
BR112013021236A8 (pt) composto, composição,e, método de tratamento de um distúrbio, uma condição ou uma doença
BR112012011478A2 (pt) composições fosfolipídicas terapêuticas concentradas.
BR112015011403A2 (pt) uso de akkermansia para o tratamento de distúrbios metabólicos
BR112014004181A2 (pt) composto, composição farmacêutica, e, método de tratamento, prevenção, e / ou retardo do início de uma doença ou patologia
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
WO2010123930A3 (en) Chemosensory receptor ligand-based therapies
WO2013186240A3 (en) Exendin-4 peptide analogues
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
BR112013010021A2 (pt) combinações farmacêuticas para o tratamento de distúrbios metabólicos.
BR112012008238A2 (pt) métodos para prevenção ou tratamento de sarcopenia e atrofia muscular em animais.
EA201590655A8 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
BR112015022514A2 (pt) composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
EA201391737A1 (ru) Новые соединения в качестве ингибиторов диацилглицеролацилтрансферазы
BR112012022552A8 (pt) uso de fenoterol e de análogos de fenoterol no tratamento de gliobastomas e astrocitomas e composição farmacêutica compreendendo os referidos compostos
WO2010071826A3 (en) Methods for treating osteoclast-related disease, compounds and compositions thereof
BRPI0812597A2 (pt) Sal, composição farmacêutica, métodos para o tratamento, prevenção ou melhora de um ou mais sintomas de uma doença mediada por crth2, de uma doença relacionada com eosinófilo, de uma doença relacionada com basófilo, e de uma doença inflamatória, e, processo para a preparação do sal
BR112014019399A2 (pt) métodos de tratamento da fibrose
BR112015001521A2 (pt) previsão de resposta ao tratamento para inibidor jak/stat

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2510 DE 12/02/2019.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI